United Therapeutics Corporation

UTHR · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.0%

Institutions100.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$3.18B	$2.88B	$2.33B	$1.94B	$1.69B	$1.48B	$1.45B	$1.63B	$1.73B	$1.60B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$384.40M	$309.70M	$257.50M	$151.60M	$122.50M	$108.10M	$117.60M	$198.70M	$105.70M	$72.70M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$1.49B	$1.38B	$1.18B	$979.70M	$555.90M	$593.60M	-$187.60M	$805.40M	$814.90M	$1.06B
Operating income as a percentage of revenue.	46.9%	47.9%	50.9%	50.6%	33.0%	40.0%	-12.9%	49.5%	47.2%	66.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$1.33B	$1.20B	$984.80M	$727.30M	$475.80M	$514.80M	-$104.50M	$589.20M	$417.90M	$713.70M
Net income divided by the number of shares outstanding — profit attributable to each share.	$30.13	$26.44	$21.04	$15.98	$10.60	$11.65	$-2.39	$13.54	$9.00	$16.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$27.86	$24.64	$19.81	$15.00	$10.06	$11.54	$-2.39	$13.39	$9.00	$15.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$1.56B	$1.70B	$1.21B	$961.20M	$894.80M	$738.70M	$738.40M	$669.20M	$705.10M	$1.02B
Everything the company owns that has value — cash, property, inventory, investments, and more.	$7.88B	$7.36B	$7.17B	$6.04B	$5.17B	$4.62B	$3.91B	$3.40B	$2.88B	$2.33B
Everything the company owes — debt, unpaid bills, and other obligations.	$783.80M	$920.00M	$1.18B	$1.25B	$1.21B	$1.22B	$1.13B	$593.20M	$758.40M	$463.40M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$7.10B	$6.44B	$5.98B	$4.80B	$3.96B	$3.40B	$2.78B	$2.79B	$2.10B	$1.85B

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$1.56B	$1.33B	$978.00M	$802.50M	$598.20M	$755.70M	-$206.60M	$778.40M	$474.20M	$643.60M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$520.50M	$246.50M	$230.40M	$138.80M	$120.80M	$59.30M	$83.70M	$184.40M	$86.30M	$38.00M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$1.04B	$1.08B	$747.60M	$663.70M	$477.40M	$696.40M	-$290.30M	$594.00M	$387.90M	$605.60M

	You	Peer avg
P/E	17.9	42.0
Revenue Growth	-1.9%	+122.1%
ROE	19.3%	-16.3%

United Therapeutics Corporation

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison